Home › Biotechnology › Argenica Therapeutics (ASX:AGN)

FDA Hold Remains as Argenica Faces Rat Study and Lower Dose Ceiling

Biotechnology By Ada Torres 3 min read

The US FDA has refused to lift the clinical hold on Argenica Therapeutics’ xaranetide stroke program, demanding a GLP rat neurotoxicity study and imposing a lower exposure limit than the company proposed for Phase 2b. Argenica plans to challenge parts of the assessment while pursuing regulatory submissions elsewhere.

  • FDA maintains clinical hold on xaranetide IND
  • GLP rat study required to assess potential Olney lesions
  • Permitted exposure limit set below proposed Phase 2b doses
  • Argenica preparing a Type A FDA meeting
  • Regulatory submissions in other jurisdictions to continue

FDA Declines to Lift Xaranetide Clinical Hold

Argenica Therapeutics Limited (ASX:AGN) has suffered a fresh setback in the United States, with the FDA deciding that the clinical hold on xaranetide for acute ischaemic stroke should remain in place. The regulator reviewed Argenica’s complete response, submitted on 23 September, but said additional information was required before US clinical dosing could resume.

The decision comes after Argenica had reported completed FDA safety assays, including a clean cardiac hERG result, as it worked towards a Phase 2b trial. The company said the FDA’s latest feedback arrived more than four weeks after the mandatory 30-day review deadline, although the timing does not alter the substance of the hold.

Rat Neurotoxicity Study Becomes a Precondition

The central new requirement is a GLP non-clinical neurotoxicity study in rats examining whether xaranetide can produce Olney lesions, a form of brain injury associated with certain high-affinity NMDA receptor blockers. The FDA wants the study completed before further human dosing under the US investigational new drug application.

Argenica argues that xaranetide does not closely match the drug profile typically associated with the lesions: it is described as a non-competitive, voltage-dependent and partial NMDA receptor inhibitor, rather than a complete blocker, and is reversible and not intended for chronic use in stroke. The company also said no microscopic brain damage has been identified in its non-clinical animal studies to date. Those points explain Argenica’s position, but they have not persuaded the FDA to remove the hold.

FDA Cuts Exposure Limit Below Proposed Trial Doses

The regulator has also revised downward the permitted plasma exposure for a future Phase 2b study. The FDA is seeking a ten-fold margin over the rat exposure level at which no effect was observed, based on non-GLP toxicokinetic data from a single rat cohort. The revised limit sits below the doses in Argenica’s September trial design, meaning any US study would need to begin at a lower dose and include a defined escalation plan.

Argenica does not accept the assessment as settled. Its preliminary review identified what it described as substantially greater variability in the data used by the FDA, while the revised limit does not align with earlier GLP toxicokinetic results. The company plans to work with its contract research organisation to verify the variability and seek further discussion with the regulator.

Type A Meeting and Non-US Regulatory Path

Argenica intends to request a Type A meeting with the FDA to discuss both the additional rat study and the exposure calculation. It has not yet quantified the study’s cost or duration, and the announcement does not establish that completing the study would automatically lead to the hold being lifted.

The company says it will continue regulatory submissions in other jurisdictions and maintains its conviction in xaranetide’s potential, citing preclinical efficacy and a signal in severe stroke patients from its Phase 2 trial. The immediate US pathway, however, now depends on the scope and outcome of the requested study, the FDA meeting and whether a revised dosing plan can satisfy the regulator.

Bottom Line?

The US program now faces an unpriced study, a disputed dosing ceiling and an uncertain timetable, making the Type A meeting the next pivotal regulatory test.

Questions in the middle?

  • Will the FDA accept Argenica’s proposed interpretation of the toxicokinetic variability?
  • How much will the requested GLP rat study cost, and how long will it take?
  • Can regulatory submissions in other jurisdictions advance while the US clinical hold remains active?

Sources